News

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...
FDA halts sale of off-brand Ozempic and other GLP-1 drugs
A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...
inews.co.uk on MSN6h
Own-label ‘Ozempic’ could be as cheap as £10 within years
The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...
Ireland U-turns to oppose EU pharma reforms after intense lobbying
Ireland has pivoted to oppose contentious European Union reforms aimed at broadening access to new drugs and medicines, ...
GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks
Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...
FDA cracking down on Ozempic copycats, potentially slimming options for consumers
The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...